Literature DB >> 617308

The narcotic-dependent mother: fetal and neonatal consequences.

S R Kandall, S Albin, L M Gartner, K S Lee, A Eidelman, J Lowinson.   

Abstract

During the years 1971--1974, 230 infants born to drug-dependent women and 33 infants born to ex-addicts were studied. Heroin abuse declined while methadone usage increased during those years. Compared to heroin abuse, methadone maintenance treatment during pregnancy was associated with more consistent prenatal care, more normal fetal growth and reduced fetal mortality. Meconium staining of amniotic fluid was increased in the heroin and heroin-methadone groups; this was not associated, however, with an increase in meconium aspiration or a reduction in Apgar scores. Of special note was the equally severe intrauterine growth retardation of infants of former heroin addicts who were free of narcotic use during pregnancy. Neonatal withdrawal from methadone appeared to be more severe than from heroin, as judged by amount of medication required to control symptoms and duration of treatment. In all groups, central nervous system signs were the most common manifestations of withdrawal. Severity of withdrawal did not correlate with late pregnancy maternal methadone dosage. Neonatal seizures occurred in 1.5% of the heroin group and 10% of the methadone group. Discharge of an infant to a parent rather than to an alternate care-taker was more likely if the mother was enrolled in a methadone treatment program. Methadone maintenance programs appear to offer significant therapeutic benefits, balancing the untoward effects of the drug on the newborn infant.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 617308     DOI: 10.1016/0378-3782(77)90017-2

Source DB:  PubMed          Journal:  Early Hum Dev        ISSN: 0378-3782            Impact factor:   2.079


  35 in total

1.  Substance use during pregnancy: time for policy to catch up with research.

Authors:  Barry M Lester; Lynne Andreozzi; Lindsey Appiah
Journal:  Harm Reduct J       Date:  2004-04-20

Review 2.  Pharmacological Management of Opioid Use Disorder in Pregnant Women.

Authors:  Christine M Wilder; Theresa Winhusen
Journal:  CNS Drugs       Date:  2015-08       Impact factor: 5.749

3.  Methamphetamine and other substance use during pregnancy: preliminary estimates from the Infant Development, Environment, and Lifestyle (IDEAL) study.

Authors:  Amelia M Arria; Chris Derauf; Linda L Lagasse; Penny Grant; Rizwan Shah; Lynne Smith; William Haning; Marilyn Huestis; Arthur Strauss; Sheri Della Grotta; Jing Liu; Barry Lester
Journal:  Matern Child Health J       Date:  2006-01-05

4.  Concentrations of methadone in breast milk and plasma in the immediate perinatal period.

Authors:  Lauren M Jansson; Robin E Choo; Cheryl Harrow; Martha Velez; Jennifer R Schroeder; Ross Lowe; Marilyn A Huestis
Journal:  J Hum Lact       Date:  2007-05       Impact factor: 2.219

5.  Teratogenic Effects of `Recreational' Drugs: Increasing the risk of congenital anomalies.

Authors:  J E Polifka; J M Friedman
Journal:  Can Fam Physician       Date:  1991-09       Impact factor: 3.275

6.  Neonatal opioid withdrawal and antenatal opioid prescribing.

Authors:  Suzanne D Turner; Tara Gomes; Ximena Camacho; Zhan Yao; Astrid Guttmann; Muhammad M Mamdani; David N Juurlink; Irfan A Dhalla
Journal:  CMAJ Open       Date:  2015-01-13

Review 7.  Maternal Use of Opioids During Pregnancy and Congenital Malformations: A Systematic Review.

Authors:  Jennifer N Lind; Julia D Interrante; Elizabeth C Ailes; Suzanne M Gilboa; Sara Khan; Meghan T Frey; April L Dawson; Margaret A Honein; Nicole F Dowling; Hilda Razzaghi; Andreea A Creanga; Cheryl S Broussard
Journal:  Pediatrics       Date:  2017-06       Impact factor: 7.124

8.  The relationship between maternal methadone dose at delivery and neonatal outcome: methodological and design considerations.

Authors:  Hendrée E Jones; Lauren M Jansson; Kevin E O'Grady; Karol Kaltenbach
Journal:  Neurotoxicol Teratol       Date:  2013 Sep-Oct       Impact factor: 3.763

9.  Can methadone concentrations predict the severity of withdrawal in infants at risk of neonatal abstinence syndrome?

Authors:  C A Kuschel; L Austerberry; M Cornwell; R Couch; R S H Rowley
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2004-09       Impact factor: 5.747

10.  The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.

Authors:  W O Farid; S A Dunlop; R J Tait; G K Hulse
Journal:  Curr Neuropharmacol       Date:  2008-06       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.